Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 9;84(7):629-634.
doi: 10.1055/a-2320-5843. eCollection 2024 Jul.

Significance of the sFlt-1/PlGF Ratio in Certain Cohorts - What Needs to be Considered?

Oliver Graupner  1 , Stefan Verlohren  2 , Tanja Groten  3 , Dietmar Schlembach  4 , Holger Stepan  5 , Bettina Kuschel  1 , Anne Karge  1 , Ulrich Pecks  6
Affiliations

Significance of the sFlt-1/PlGF Ratio in Certain Cohorts - What Needs to be Considered?

Oliver Graupner et al. Geburtshilfe Frauenheilkd. .

Abstract

The sFlt-1/PlGF ratio is an established tool in clinical practice, where it is part of a diagnostic algorithm and informs the prognosis of preeclampsia (PE). Maternal and gestational comorbidities can affect the performance of the sFlt-1/PlGF ratio and its constituent elements, and a good understanding of the potential pitfalls is required. The objective of this paper was to provide a current narrative review of the literature on the diagnostic and predictive performance of the sFlt-1/PlGF ratio in specific patient cohorts. Potential factors which can negatively affect the clinical interpretability and applicability of the sFlt-1/PlGF ratio include chronic kidney disease, twin pregnancy, and maternal obesity. Pathophysiological mechanisms related to these factors and disorders can result in different concentrations of sFlt-1 and/or PlGF in maternal blood, meaning that the use of standard cut-off values in specific cohorts can lead to errors. To what extent the cut-off values should be adapted in certain patient cohorts can only be clarified in large prospective cohort studies. This applies to the use of the ratio both for diagnosis and prognosis.

Keywords: angiogenic factors; preeclampsia; sFlt-1/PlGF ratio.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest HS: lectures and consultancy work for Sanofi, Alexion, Roche Diagnostics and Norgine. SV: Speaker fees: Thermo Fisher Scientific, Roche Diagnostics, Comanche Biopharma, Alexion Advisory Board: Siemens, Beckman Coulter, Comanche Biopharma.

References

    1. Verlohren S, Brennecke SP, Galindo A et al.Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia. Pregnancy Hypertens. 2022;27:42–50. doi: 10.1016/j.preghy.2021.12.003. - DOI - PubMed
    1. Rana S, Burke SD, Karumanchi SA. Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders. Am J Obstet Gynecol. 2022;226 2:S1019–S1034. doi: 10.1016/j.ajog.2020.10.022. - DOI - PMC - PubMed
    1. Greco M, Palumbo C, Sicuro F et al.Soluble Fms-Like Tyrosine Kinase-1 Is A Marker of Endothelial Dysfunction During Sepsis. J Clin Med Res. 2018;10:700–706. doi: 10.14740/jocmr3505w. - DOI - PMC - PubMed
    1. Dupont V, Kanagaratnam L, Goury A et al.Excess Soluble fms-like Tyrosine Kinase 1 Correlates With Endothelial Dysfunction and Organ Failure in Critically Ill Coronavirus Disease 2019 Patients. Clin Infect Dis. 2021;72:1834–1837. doi: 10.1093/cid/ciaa1007. - DOI - PMC - PubMed
    1. Greco M, Suppressa S, Lazzari RA et al.sFlt-1 and CA 15.3 are indicators of endothelial damage and pulmonary fibrosis in SARS-CoV-2 infection. Sci Rep. 2021;11:19979. doi: 10.1038/s41598-021-99470-y. - DOI - PMC - PubMed

LinkOut - more resources